METHOD FOR PREDICTING THERAPEUTIC RESPONSIVENESS OF LUNG CANCER WITH RESPECT TO EGFR-TARGETING THERAPEUTIC AGENT

摘要

The present invention relates to a method for predicting whether non-small-cell lung-cancer patients will be responsive to a drug targeting epidermal growth factor receptor (EGFR), thereby increasing therapeutic effectiveness in acquired-resistance patients. The present invention makes it possible to predict in advance whether a lung-cancer patient will react to a medical therapeutic agent, and overcomes the problem of a low rate of therapeutic success due to resistance, and at the same time is useful in estimating anticancer agent prognosis and determining future treatment strategy.